265 related articles for article (PubMed ID: 24100024)
21. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day SJ; Maio M; Chiarion-Sileni V; Gajewski TF; Pehamberger H; Bondarenko IN; Queirolo P; Lundgren L; Mikhailov S; Roman L; Verschraegen C; Humphrey R; Ibrahim R; de Pril V; Hoos A; Wolchok JD
Ann Oncol; 2010 Aug; 21(8):1712-1717. PubMed ID: 20147741
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
[TBL] [Abstract][Full Text] [Related]
25. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
Chiarion-Sileni V; Pigozzo J; Ascierto PA; Simeone E; Maio M; Calabrò L; Marchetti P; De Galitiis F; Testori A; Ferrucci PF; Queirolo P; Spagnolo F; Quaglino P; Carnevale Schianca F; Mandalà M; Di Guardo L; Del Vecchio M
Br J Cancer; 2014 Apr; 110(7):1721-6. PubMed ID: 24619072
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
[TBL] [Abstract][Full Text] [Related]
27. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
[TBL] [Abstract][Full Text] [Related]
28. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Wilgenhof S; Du Four S; Vandenbroucke F; Everaert H; Salmon I; Liénard D; Marmol VD; Neyns B
J Immunother; 2013 Apr; 36(3):215-22. PubMed ID: 23502769
[TBL] [Abstract][Full Text] [Related]
29. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
Robert C; Schadendorf D; Messina M; Hodi FS; O'Day S;
Clin Cancer Res; 2013 Apr; 19(8):2232-9. PubMed ID: 23444228
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; Prat A; Arance A
Future Oncol; 2016 Dec; 12(23):2683-2688. PubMed ID: 27581765
[TBL] [Abstract][Full Text] [Related]
35. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM
Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O
Br J Cancer; 2016 May; 114(10):1084-9. PubMed ID: 27124339
[TBL] [Abstract][Full Text] [Related]
37. Ipilimumab: a novel treatment for metastatic melanoma.
Culver ME; Gatesman ML; Mancl EE; Lowe DK
Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
[TBL] [Abstract][Full Text] [Related]
38. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
40. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
